BioArctic Stock

BioArctic CROIC

The Cash Return on Invested Capital (CROIC) of BioArctic (BIOA B.ST) as of Aug 4, 2026 is 71.16 %. In the previous year, Cash Return on Invested Capital (CROIC) was -36.13 % — a change of -296.93% (higher).

CROIC

71.16 %

YoY

-296.93%

Last updated:

Cash Return on Invested Capital (CROIC) of BioArctic is 2026 71.16 % . Cash Return on Invested Capital (CROIC) of BioArctic was 2025 -36.13 % . It decreases by -296.93% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Cash Return on Invested Capital (CROIC) of BioArctic is 71.16 % in 2026.

Cash Return on Invested Capital (CROIC) of BioArctic changed from -36.13 % to 71.16 %, representing a -296.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) BioArctic since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — BioArctic

All Key Metrics — BioArctic